HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $830,945 | -96.6% | 23,037 | -96.4% | 0.00% | -97.7% |
| Q1 2023 | $24,205,395 | -31.3% | 633,815 | +2.4% | 0.04% | -36.8% |
| Q4 2022 | $35,231,228 | +26.2% | 619,178 | -12.3% | 0.07% | +19.3% |
| Q3 2022 | $27,927,000 | -15.0% | 706,278 | -5.4% | 0.06% | +83.9% |
| Q2 2022 | $32,855,000 | +34.6% | 746,689 | +22.0% | 0.03% | +72.2% |
| Q1 2022 | $24,404,000 | +3.5% | 611,960 | +4.4% | 0.02% | +12.5% |
| Q4 2021 | $23,575,000 | +3.3% | 586,274 | +4.5% | 0.02% | -11.1% |
| Q3 2021 | $22,826,000 | +99.6% | 561,113 | +122.9% | 0.02% | +80.0% |
| Q2 2021 | $11,434,000 | +708.6% | 251,786 | +642.6% | 0.01% | +900.0% |
| Q1 2021 | $1,414,000 | -63.8% | 33,906 | -62.9% | 0.00% | -75.0% |
| Q4 2020 | $3,905,000 | +92.7% | 91,428 | +18.6% | 0.00% | +100.0% |
| Q3 2020 | $2,026,000 | -39.9% | 77,101 | -38.7% | 0.00% | -50.0% |
| Q2 2020 | $3,372,000 | +804.0% | 125,785 | +506.4% | 0.00% | +300.0% |
| Q1 2020 | $373,000 | -88.3% | 20,742 | -88.4% | 0.00% | -66.7% |
| Q4 2019 | $3,182,000 | +66.9% | 179,452 | +61.7% | 0.00% | +50.0% |
| Q2 2019 | $1,906,000 | +7.2% | 110,968 | +0.5% | 0.00% | 0.0% |
| Q1 2019 | $1,778,000 | +385.8% | 110,410 | +447.7% | 0.00% | – |
| Q3 2018 | $366,000 | -62.8% | 20,158 | -65.4% | 0.00% | -100.0% |
| Q2 2018 | $983,000 | -13.9% | 58,295 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $1,142,000 | -12.0% | 58,295 | -8.9% | 0.00% | 0.0% |
| Q4 2017 | $1,297,000 | -2.2% | 63,991 | -16.1% | 0.00% | 0.0% |
| Q3 2017 | $1,326,000 | +48.0% | 76,309 | +9.9% | 0.00% | 0.0% |
| Q2 2017 | $896,000 | -51.9% | 69,421 | -51.6% | 0.00% | -50.0% |
| Q1 2017 | $1,862,000 | +39.6% | 143,521 | +6.3% | 0.00% | +100.0% |
| Q4 2016 | $1,334,000 | -51.2% | 134,982 | -40.8% | 0.00% | -66.7% |
| Q3 2016 | $2,735,000 | +46.8% | 227,920 | +5.6% | 0.00% | +50.0% |
| Q2 2016 | $1,863,000 | +86.7% | 215,889 | +104.9% | 0.00% | +100.0% |
| Q1 2016 | $998,000 | -44.9% | 105,369 | +1.3% | 0.00% | -50.0% |
| Q4 2015 | $1,810,000 | +19.9% | 104,045 | -7.4% | 0.00% | 0.0% |
| Q3 2015 | $1,510,000 | -35.7% | 112,380 | +8.0% | 0.00% | -33.3% |
| Q2 2015 | $2,349,000 | +86.4% | 104,045 | +17.9% | 0.00% | +200.0% |
| Q1 2015 | $1,260,000 | +69.1% | 88,245 | +14.2% | 0.00% | 0.0% |
| Q4 2014 | $745,000 | -41.6% | 77,245 | -44.9% | 0.00% | -50.0% |
| Q3 2014 | $1,276,000 | +10.2% | 140,245 | +19.6% | 0.00% | +100.0% |
| Q2 2014 | $1,158,000 | -13.4% | 117,245 | +11.4% | 0.00% | -50.0% |
| Q1 2014 | $1,337,000 | -11.0% | 105,245 | +5.0% | 0.00% | 0.0% |
| Q4 2013 | $1,503,000 | +18.2% | 100,245 | -13.0% | 0.00% | 0.0% |
| Q3 2013 | $1,272,000 | +96.9% | 115,245 | +41.8% | 0.00% | +100.0% |
| Q2 2013 | $646,000 | – | 81,245 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |